| Issue Date | Title | Author(s) |
| 2-Nov-2023 | Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study | Wang, Jing; Li, Siqi; Jiang, Hao; Chang, Ying-Jun; Zhao, Xiao-Su; Jia, Jinsong; Zhu, Xiaolu; Gong, Lizhong; Liu, Xiaohong; Yu, Wen-Jing; Huang, Xiaojun |
| Jan-2021 | Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center | Duan, Wenbing; Liu, Xiaohong; Zhao, Xiaosu; Jia, Jinsong; Wang, Jing; Gong, Lizhong; Jiang, Qian; Zhao, Ting; Wang, Yu; Zhang, Xiaohui; Xu, Lanping; Shi, Hongxia; Chang, Yingjun; Liu, Kaiyan; Huang, Xiaojun; Qin, Yazhen; Jiang, Hao |
| 2023 | Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease | He, Qing; Dou, Xuelin; Liu, Yang; Wen, Lei; Wang, Fengrong; Peng, Nan; Gong, Lizhong; Li, Yue; Lu, Yao; Wang, Liru; Zhang, Xiaohui; Huang, Xiaojun; Lu, Jin |
| Feb-2020 | Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA | Wang, Jing; Lu, RunQing; Wu, Ying; Jia, JinSong; Gong, Lizhong; Liu, XiaoHong; Lu, ShengYe; Wang, Yu; Yan, ChenHua; Liu, KaiYan; Zhang, XiaoHui; Xu, LanPing; Jiang, Qian; Zhao, XiaoSu; Shi, HongXia; Lai, YueYun; Huang, XiaoJun; Ruan, GuoRui; Jiang, Hao |
| 15-Nov-2022 | Interferon-alpha-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia-a Prospective, Single-Arm Study | Liu, Xiaohong; Li, Yao; Yu, Wenjing; Zhu, Xiaolu; Jia, Jinsong; Gong, Lizhong; Zhao, Xiaosu; Chang, Yingjun; Huang, Xiao-Jun; Jiang, Hao |
| Jan-2021 | The loss or absence of minimal residual disease of <0 center dot 1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis | Duan, Wenbing; Liu, Xiaohong; Jia, Jinsong; Wang, Jing; Gong, Lizhong; Jiang, Qian; Zhao, Ting; Wang, Yu; Zhang, Xiaohui; Xu, Lanping; Zhao, Xiaosu; Qin, Yazhen; Shi, Hongxia; Chang, Yingjun; Huang, Xiaojun; Jiang, Hao |
| 2-Nov-2023 | Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a<3log Reduction of MRD2 Predicted Poor Survival | Duan, Wenbing; Jia, Jinsong; Wang, Jing; Liu, Xiaohong; Gong, Lizhong; Yu, WenJing; Zhu, Xiaolu; Ting, Zhao; Jiang, Qian; Ruan, Guorui; Zhao, Xiaosu; Wang, Yu; Shi, Hongxia; Xu, Lanping; Zhang, Xiaohui; Huang, Xiaojun; Jiang, Hao |
| 2022 | Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study | Liu, Jing; Liu, Xiaohong; Jia, Jinsong; Gong, Lizhong; Lu, Shengye; Wang, Jing; Huang, Xiao-jun; Jiang, Hao |
| 2022 | Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study | Liu, Jing; Liu, Xiaohong; Jia, Jinsong; Gong, Lizhong; Lu, Shengye; Wang, Jing; Huang, Xiao-jun; Jiang, Hao |
| 23-Nov-2021 | Safety and Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single Institution Experience | Yu, Wen-Jing; Jia, Jinsong; Wang, Jing; Tang, Fei-Fei; Gong, Lizhong; Liu, Xiaohong; Zhu, Xiaolu; Zhao, Xiaosu; Huang, Xiao Jun; Jiang, Hao |
| 21-Nov-2024 | Sintilimab plus decitabine for higher-risk treatment-na?ve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial | Wang, Jing; Li, Siqi; Jiang, Hao; Chang, Ying-Jun; Zhao, Xiaosu; Jia, Jinsong; Zhu, Xiaolu; Gong, Lizhong; Liu, Xiaohong; Yu, Wenjing; Huang, Xiaojun |
